ALK and non-small cell lung carcinoma: Similarly, the overall safety profile of first-line ceritinib in advanced ALK-rearranged NSCLC (NCT01828099) was consistent with those safety profiles of ceritinib in ALK-rearranged NSCLC patients who had progressed on multiple lines of chemotherapy (NCT01283516 and NCT01685138) [3, 5, 25].